VANCOUVER, BC / ACCESS Newswire / June 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE ...

Though the medication cannot actually increase the size of your bits, it can improve your blood flow and reduce the amount of ...

The blockbuster weight loss drug, semaglutide, now has competition in orforglipron, which is just as safe as injectable ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...

Oral semaglutide reduces cardiovascular events by 14% at four years Tablet form of GLP-1 inhibitor offers alternative for patients hesitant to take injections ...

CHICAGO — Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 inhibitor use, according to data presented at the American ...

A NEW ‘Ozempic pill’ leads to faster weight loss than the popular ‘skinny jabs’, studies have suggested. The new weight loss ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Semaglutide: A High-Growth Market Segment Semaglutide is a GLP-1 analog that has rapidly become a blockbuster drug for type 2 diabetes and obesity, with growing use in cardiovascular risk reduction.

Despite its success, most current Semaglutide formulations still require weekly injections or large daily oral tablets, which can affect patient adherence. A rapidly dissolving oral thin film promises ...